3D Scaffold Cell Culture for Efficient Stem Cell Gene Editing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current ex vivo gene therapy protocols for hematopoietic stem cells face challenges in achieving efficient genetic modification with minimal side effects, such as mucositis, bone marrow aplasia, and prolonged neutropenia, while maintaining long-term repopulating capacity and engraftment potential.

Innovation Solution

Culturing cells on a three-dimensional scaffold before, during, and after genetic modification to enhance gene editing efficiency and preserve biological properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional ex vivo gene therapy protocols are used for hematopoietic stem cells, then genetic modification can be achieved, but side effects such as mucositis, bone marrow aplasia, and prolonged neutropenia occur

Engineering Contradiction:

Improvegenetic modification efficiencyVSAvoidside effects (mucositis, bone marrow aplasia, prolonged neutropenia)

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by culturing hematopoietic stem cells on a three-dimensional scaffold before genetic modification. This pre-culture step prepares the cells in a controlled 3D environment that mimics physiological conditions, enhancing their resilience and reducing the severity of side effects during subsequent gene therapy procedures and conditioning regimens.

Inventive Principle:

Principle #10Preliminary action

2Productivity

If hematopoietic stem cells are cultured in conventional two-dimensional culture, then cell expansion is achieved, but engraftment potential and long-term repopulating capacity are lost

Engineering Contradiction:

Improvecell expansionVSAvoidengraftment potential and long-term repopulating capacity

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent fundamentally changes the culture dimension from two-dimensional to three-dimensional by using a 3D scaffold system. This dimensional transition allows hematopoietic stem cells to maintain their physiological architecture, cell-cell interactions, and niche environment, thereby preserving engraftment potential and long-term repopulating capacity while achieving controlled cell expansion.

Inventive Principle:

Principle #17Another dimension (Dimensionality change)

3Reliability

If genetic modification is performed on quiescent HSCs, then gene editing can be achieved, but efficiency is low due to limited HDR machinery expression and high NHEJ activity

Engineering Contradiction:

Improvegene editing efficiencyVSAvoidHDR machinery expression and NHEJ activity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies preliminary action by performing 3D scaffold culture before genetic modification. This pre-culture step activates quiescent HSCs and upregulates HDR machinery expression in a controlled manner, creating optimal cellular conditions for efficient gene editing while suppressing error-prone NHEJ pathways, thereby significantly improving gene editing efficiency.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260035661A13D cell culture methods

Publication Date: 2026.02.05 FONDAZIONE TELETHON ETS (50)

AI summary

The present invention is directed to a method for ex-vivo-engineering of cells, in particular stem cells or T cells, preferably hematopoictic stem and/or progenitor cells, mesenchymal stem cells, or T cells comprising a step of culturing the cells on a three-dimensional scaffold. The method of the invention is capable of improving the efficiency of genetic modification of cells and the functionality of the engineered cells.